Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVANCE MPI 1: Regadenoson vs Adenoscan in MPI
NCT00208299Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Oct 2003
- Primary completion
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of regadenoson in coronary artery disease (CAD) (2 arms), sponsored by Gilead Sciences. Primary endpoint: Non-inferiority of regadenoson to Adenoscan for use in single photon emission computed tomography (SPECT) myocardial perfusion imaging in assessing reversible perfusion defects. Started Oct 2003; status: completed.
02
Drugs
regadenoson
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT00208299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00208299.